[New pneumococcal vaccine].
Streptococcus Pneumoniae is the main pathogen bacteria responsible for invasive diseases (bacteremia, meningitis) in children less than 2 years of age. The new conjugate heptavalent pneumococcal vaccine (7 polysaccharide serotypes 4, 6B, 9V, 14, 18C, 19F, 23F conjugated with the CRP 197 protein derived from diphteria anatoxin) is a great advance. This vaccine is well tolerated, immunogenic and efficient in infant. His efficacy in invasive pneumococcal diseases is more than 95%. The reduction of pneumonia (with 2.5 cm X-Ray opacity) was 32.2% in the first year of age and 23.4% in the two first years in the vaccinated group. The efficacy in acute otitis media is poor French indications of this vaccine, limited to infants under 2 years of age with further risk factor, might be extended to all the infants under 2 years of age.
Gaudelus
Joël
J
Service de Pédiatrie-CHU Jean Verdier-93140 Bondy.
D005602:France / Q000453:epidemiology; D006801:Humans; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000008:administration & dosage*; D012307:Risk Factors; D014481:United States / Q000453:epidemiology; D018074:Vaccines, Conjugate / Q000008:administration & dosage
D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate